RXi Pharmaceuticals (RXII) Trading Down 5.6%
RXi Pharmaceuticals Corporation (NASDAQ:RXII) shares were down 5.6% during mid-day trading on Tuesday . The stock traded as low as $0.63 and last traded at $0.67. Approximately 748,577 shares were traded during trading, an increase of 25% from the average daily volume of 600,605 shares. The stock had previously closed at $0.71.
RXi Pharmaceuticals (NASDAQ:RXII) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.11) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.11). During the same quarter last year, the business posted ($0.34) EPS. equities analysts expect that RXi Pharmaceuticals Corporation will post -0.74 earnings per share for the current fiscal year.
In related news, insider Alexey Eliseev sold 176,800 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $0.54, for a total transaction of $95,472.00. Following the sale, the insider now owns 1,100,931 shares in the company, valued at $594,502.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 5.71% of the stock is currently owned by company insiders.
RXi Pharmaceuticals Company Profile
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.
Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.